[go: up one dir, main page]

MX2018001575A - Compuestos triciclicos y su uso en el tratamiento del cancer. - Google Patents

Compuestos triciclicos y su uso en el tratamiento del cancer.

Info

Publication number
MX2018001575A
MX2018001575A MX2018001575A MX2018001575A MX2018001575A MX 2018001575 A MX2018001575 A MX 2018001575A MX 2018001575 A MX2018001575 A MX 2018001575A MX 2018001575 A MX2018001575 A MX 2018001575A MX 2018001575 A MX2018001575 A MX 2018001575A
Authority
MX
Mexico
Prior art keywords
treatment
cancer
compounds
tricycle
tricycle compounds
Prior art date
Application number
MX2018001575A
Other languages
English (en)
Other versions
MX395659B (es
Inventor
Simeonov Anton
S Dexheimer Thomas
Patrick Coussens Nathan
jadhav Ajit
Chester STAFFORD William
Karen Luci Diane
Joseph MALONEY David
Original Assignee
Elias Set Jenoe Arner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elias Set Jenoe Arner filed Critical Elias Set Jenoe Arner
Publication of MX2018001575A publication Critical patent/MX2018001575A/es
Publication of MX395659B publication Critical patent/MX395659B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos de la Fórmula (I),(ver formula) (I) o sales de aquel aceptables desde el punto de vista farmacéutico, en donde X, Y, Z, R1 y R2 tienen significados proporcionados en la descripción, en donde los compuestos son útiles en el tratamiento de tipos de cáncer.
MX2018001575A 2015-08-07 2016-08-05 Compuestos triciclicos y su uso en el tratamiento del cancer MX395659B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1514018.9A GB201514018D0 (en) 2015-08-07 2015-08-07 Novel tricyclic compounds and their use in the treatment of cancer
PCT/US2016/045730 WO2017027358A1 (en) 2015-08-07 2016-08-05 Tricyclic compounds and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2018001575A true MX2018001575A (es) 2018-11-09
MX395659B MX395659B (es) 2025-03-25

Family

ID=54200421

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001575A MX395659B (es) 2015-08-07 2016-08-05 Compuestos triciclicos y su uso en el tratamiento del cancer

Country Status (12)

Country Link
US (1) US10881653B2 (es)
EP (1) EP3331883A1 (es)
JP (1) JP6545908B2 (es)
KR (2) KR102428549B1 (es)
CN (1) CN108026096A (es)
AU (1) AU2016307438B2 (es)
CA (1) CA2995075C (es)
GB (1) GB201514018D0 (es)
MA (1) MA42914A (es)
MX (1) MX395659B (es)
RU (1) RU2736501C2 (es)
WO (1) WO2017027358A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021513573A (ja) * 2018-02-12 2021-05-27 シンダ ファーマ エービー 癌の処置に使用されるチオレドキシン還元酵素阻害剤
FI3853234T3 (fi) 2018-09-18 2025-07-28 Nikang Therapeutics Inc Fuusioituja trisyklisiä rengasjohdannaisia SRC-homologia-2-fosfataasin estäjinä

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550458B2 (en) * 2005-10-18 2009-06-23 Bristol-Myers Squibb Company Tricycloundecane compounds useful as modulators of nuclear hormone receptor function
WO2008027912A2 (en) * 2006-08-28 2008-03-06 Dan Theodorescu Prediction of an agent's or agents' activity across different cells and tissue types
PL219045B1 (pl) 2010-10-16 2015-03-31 Inst Chemii Organicznej Polskiej Akademii Nauk Nowe estry (acyloksymetylo)akrylamidu, kompozycja farmaceutyczna zawierająca je oraz ich zastosowanie

Also Published As

Publication number Publication date
US10881653B2 (en) 2021-01-05
US20200113889A1 (en) 2020-04-16
AU2016307438B2 (en) 2019-07-11
WO2017027358A1 (en) 2017-02-16
RU2018107941A3 (es) 2019-09-09
KR20200102529A (ko) 2020-08-31
CA2995075C (en) 2022-05-31
RU2018107941A (ru) 2019-09-09
KR102428549B1 (ko) 2022-08-03
RU2736501C2 (ru) 2020-11-17
JP2018522948A (ja) 2018-08-16
MX395659B (es) 2025-03-25
KR20180032647A (ko) 2018-03-30
JP6545908B2 (ja) 2019-07-17
CN108026096A (zh) 2018-05-11
MA42914A (fr) 2018-08-01
WO2017027358A8 (en) 2017-04-20
EP3331883A1 (en) 2018-06-13
CA2995075A1 (en) 2017-02-16
GB201514018D0 (en) 2015-09-23
AU2016307438A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
CY1123451T1 (el) Αγωνιστες τριαζολης του υποδοχεα αρj
MX390537B (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CY1119199T1 (el) Αναστολεις cdc7
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CO2019007888A2 (es) Inhibidores selectivos de jak1
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
CL2016003260A1 (es) Profármacos de gemcitabina
DOP2017000035A (es) Inhibidores de la proteina quinasa c y metodos de su uso
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
UY36075A (es) Derivados de tubulisina
LT3806898T (lt) Gremlin-1 antagonistas, skirtas naudoti vėžio gydymui
MX2018004664A (es) Antagonistas de ep4.
MX2019009266A (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer.
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos